Using Vosevi to treat patients with chronic Hepatitis C who have tried other medications
Official title: A Prospective Cohort Study: the Efficacy of Vosevi in Treating Direct Antiviral Agent Therapy Failure Patients
Run by The Third Affiliated Hospital of Guangzhou Medical University · NCT06180590 · Data updated 2026-11-12
This study is testing if Vosevi can help people with chronic Hepatitis C who haven't had success with other treatments feel better and clear the virus from their system.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 70 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | The Third Affiliated Hospital of Guangzhou Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | February 28, 2023 |
| Main results expected | February 28, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | March 13, 2024 |
| Trial ID | NCT06180590 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20-70 who have previously received direct antiviral agents and still have positive HCV-RNA.
✕Probably not a fit
Patients with concurrent infections, significant comorbidities, or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the efficacy of Vosevi, a combination of Sofosbuvir, Velpatasvir, and Voxilaprevir, in treating patients with chronic Hepatitis C who have previously experienced treatment with direct antiviral agents (DAAs). Participants aged 20-70 with persistent HCV-RNA despite prior DAA therapy will receive Vosevi or a combination of Sofosbuvir/Velpatasvir and ribavirin. The study aims to assess the sustained virologic response (SVR) rates among these patients, contributing to the understanding of treatment options for DAA-experienced individuals.
Why it matters
Potential benefit: If successful, this study could provide an effective treatment option for patients with chronic Hepatitis C who have not responded to previous antiviral therapies.
How similar studies have gone: Other studies have shown promising results with similar antiviral combinations, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age of 20-70 years. * Accepted the standard direct antiviral agent before * HCV-RNA still positive * Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg) or Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin（500mg）twice a day treatment for rescue therapy. * The good compliance of patients. Exclusion Criteria: * Patients with antibodies against HIV, HBV, HDV, concretion or other forms of infectious disease. * Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity. * Concurrent treatment with glucocorticoids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators. * Pregnancy.
Where it's running
-
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Xingfei Pan, PhD
- Email: panxf0125@163.com
- Phone: 13662517686
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
-
AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function
This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.